KESIMPTA (ofatumumab) injection

KESIMPTA is a prescription medicine used for the treatment of relapsing forms of multiple sclerosis (MS),. Brand Name: KESIMPTA (ofatumumab) injection, for subcutaneous use Initial U.S. Approval: 2009. FDA approved ofatumumab (brand name KESIMPTA) is not (yet) registered or available in India but on request Indian patient can buy KESIMPTA at the lowest price.

KESIMPTA (ofatumumab) injection Price In India and Overseas
KESIMPTA (ofatumumab) injection

Submit a request to access drug used to treat, diagnose or prevent serious or life-threatening conditions.We’ll get back to you within 1 business days!

For Indian Patient Enquiry under NPP.

For any urgent inquiries or assistance needed, please reach out to our Support Team. Rest assured, we will respond within 24 hours, from Monday to Saturday, during the hours of 9:00 A.M to 18:00 PM.

KESIMPTA (ofatumumab) injection

Ofatumumab injection is used in combination with chlorambucil to treat a type of cancer of the white blood cells called chronic lymphocytic leukemia (CLL) in patients who have not received any treatments in the past.

KESIMPTA is a CD20-directed cytolytic antibody indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults

Ofatumumab is a fully human monoclonal antibody to CD20, which appears to provide rapid B-cell depletion. Under the brand name Kesimpta, it is approved for the treatment of multiple sclerosis in the United States as well as in the European Union and other regions. Under the brand name Arzerra, it is approved for the treatment of certain types of chronic lymphocytic leukemia (CLL) in the United States.

Drug (Brand / Generic): KESIMPTA / ofatumumab
Current Indications: multiple sclerosis (MS)
Marketed by:: Novartis Pharmaceuticals Corporation
Approval Date: 2009

Dosage forms and strengths of KESIMPTA (ofatumumab) injection
• Injection: 20 mg/0.4 mL solution in a single-dose prefilled Sensoready® pen
• Injection: 20 mg/0.4 mL solution in a single-dose prefilled syringe

For more highlights of prescribing information regarding Indications and usage, dosage and administration, dosage forms and strengths, patient counseling information and medication guide. Click Here

Alleviare Life Sciences

About Us

Alleviare Life Sciences Pvt. Ltd. (India) serves as a facilitator for medical and pharmaceutical products, commencing its operations in 2005. Headquartered in Delhi, India, Alleviare operates nationwide, providing a range of comprehensive services to patients, doctors, hospitals, and government healthcare facilities.

Our specialization lies in facilitating access to medicines, leveraging our expertise in sourcing and providing documentation assistance for programs such as Named Patient Program, Managed Access Program, and Early Access Program. We take pride in ensuring smooth and efficient access to medications for those who require them.

Alleviare India, a certified pharmaceutical facilitator / supplier / importer of specialty medicines or drugs based in India.